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Background: To unravel true links between diet and health, it is important that dietary exposure is accurately
measured. Currently, mainly self-reporting methods (e.g. food frequency questionnaires and 24-h recalls) are used to
assess food intake in epidemiological studies. However, these traditional instruments are subjective measures and
contain well-known biases. Especially, estimating the intake of the group of confectionary products, such as products
containing cocoa and liquorice, remains a challenge. The use biomarkers of food intake (BFIs) may provide a more
objective measurement. However, an overview of current candidate biomarkers and their validity is missing for both
cocoa- and liquorice-containing foods.
Objective: The purpose of the current study was to (1) identify currently described candidate BFIs for cocoa (products)
and liquorice, (2) to evaluate the validity of these identified candidate BFIs and (3) to address further validation and/or
identification work to be done.
Methods: This systematic review was based on a comprehensive literature search of three databases (PubMed, Scopus
and ISI web of Science), to identify candidate BFIs. Via a second search step in the Human Metabolome Database
(HMDB), the Food Database (FooDB) and Phenol-Explorer, the specificity of the candidate BFIs was evaluated, followed
by an evaluation of the validity of the specific candidate BFIs, via pre-defined criteria.
Results: In total, 37 papers were included for cocoa and 8 papers for liquorice. For cocoa, 164 unique candidate BFIs
were obtained, and for liquorice, four were identified in total. Despite the high number of identified BFIs for cocoa,
none of the metabolites was specific. Therefore, the validity of these compounds was not further examined. For
liquorice intake, 18-glycyrrhetinic acid (18-GA) was found to have the highest assumed validity.
Conclusions: For cocoa, specific BFIs were missing, mainly because the individual BFIs were also found in foods
having a similar composition, such as tea (polyphenols) or coffee (caffeine). However, a combination of individual
BFIs might lead to discriminating profiles between cocoa (products) and foods with a similar composition. Therefore,
studies directly comparing the consumption of cocoa to these similar products are needed, enabling efforts to find a
unique profile per product. For liquorice, we identified 18-GA as a promising BFI; however, important information on its
validity is missing; thus, more research is necessary. Our findings indicate a need for more studies to determine acceptable
BFIs for both cocoa and liquorice.
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Several epidemiological studies have observed relation-
ships between habitual intake of cocoa (products) and
liquorice and health. Beneficial effects associated to the
consumption of cocoa and cocoa product intake include
a positive association with flow-mediated vasodilatation
and inverse associations with blood pressure, serum in-
sulin, HOMA-IR, calcified atherosclerotic plaques in the
coronary arteries, incident cardiovascular diseases, car-
diac mortality, cardiovascular mortality and all-cause
mortality [1–6]. Liquorice has been widely exploited for
medicinal purposes including its use as remedy in case
of sore throat or cough [7, 8]. However, even though
beneficial effects have been reported for both the con-
sumption of cocoa- and liquorice-containing products,
many of these products are often energy-dense foods,
high in sugar and fats. Therefore, intake of these
products in high amounts is not recommended, as it is
associated with obesity and related diseases [9, 10]. Also,
contraindications for the use of liquorice in large
amounts have been reported in specific conditions, espe-
cially during pregnancy and in patients with hyperten-
sion, hypokalaemia or hepatic or kidney failure [11, 12].
To unravel true links between diet and health in epi-
demiology studies, it is essential to accurately assess
dietary exposure. Currently, the use of self-reporting
methods, such as 24-h dietary recalls, food diaries, and
food-frequency questionnaires are the most frequently
used instruments to assess food exposure in epidemio-
logical studies. However, these conventional methods are
subjective measures; they contain well-known biases,
such as reporting and recall biases [13, 14], and do not
take into account individual characteristics and differen-
tial metabolic responses to the intake of different food
components and food bioactives. Therefore, the ob-
served relationships between nutrition and health could
have been affected, thereby possibly leading to inconsist-
encies in the field of nutritional research. In particular,
accurate estimation of the intake of cocoa- and
liquorice-containing products is difficult. This is partly
due to the fact that the moments on which these types
of foods are consumed are often not planned. Further-
more, people have difficulties determining accurate por-
tion sizes, they might underreport their intake of these
types of food as they are believed to be unhealthy, and
they might not be able to recall all the foods that contain
these types of compounds. Hence, there is an urgent
need for more accurate measurements of food intake, es-
pecially for cocoa- and liquorice-containing foods. As a
result of the application of metabolomics in the nutrition
field, candidate biomarkers of food intake (BFIs) are in-
creasingly described in the literature [15]. BFIs are ob-
jective measures of actual food intake and as such could
be used in conjunction with the conventional methods,to improve the quality of dietary assessment in nutri-
tional science and to assist in examining true associa-
tions between nutrition and health [16]. In the literature,
many different biomarker classification schemes exist
[17, 18]. In this manuscript, we defined BFIs according
to the definition proposed by Gao et al. [18]. In short,
we included all biomarkers described in the literature
after the intake of cocoa products, liquorice products or
their components that can be used to estimate recent or
average intakes of these entities. Since cocoa and cocoa
products are consumed all over the world, the number
of potential BFIs for cocoa (products) is rapidly rising in
the literature. Liquorice is also widely consumed, espe-
cially in Europe, and can be used as an ingredient in dif-
ferent food products. However, potential BFIs for the
consumption of liquorice (products) are less well ex-
plored [19]. Currently, three approaches are used for BFI
identification, namely, (1) acute or chronic intervention
studies where metabolic profiles are examined after a
specific load of the food of interest, (2) dietary pattern
studies where metabolic profiles are examined after sub-
jects adhere to a certain dietary pattern and (3) observa-
tional studies where metabolic profiles are compared
between consumers and non-consumers of a specific
food of interest [20, 21]. To examine the validity of a
candidate BFI, it is important that the BFI has been eval-
uated using all of these approaches. An overview of
already identified candidate BFIs for cocoa (products)
and liquorice, as well as an evaluation of their validity, is
needed to identify known and accepted BFIs, as well as
to identify what information is still missing and requires
further investigation. Hence, the aims of this systematic
review were (1) to identify currently described candidate
BFIs for cocoa (products) and liquorice in the literature,
(2) to evaluate the validity of these identified candidate
BFIs and (3) to address further identification and/or val-
idation work to be done. This systematic review is per-
formed in the frame of the FoodBAll (Food Biomarkers
Alliance) project under the Joint Programming Initia-
tive—A Healthy Diet for a Healthy Life (JPI-HDHL)
(http://www.foodmetabolome.org/).
Materials and methods
Identification of biomarkers
In order to identify papers on BFIs for both cocoa and
liquorice, we carried out an extensive literature search
following the Biomarker of Food Intake Reviews
(BFIRev) methodology proposed previously [22]. In
short, for this systematic review, all elements of the
PRISMA statement [23] relevant for a literature search
on biomarkers were used. Original papers and reviews
were searched in Scopus, PubMed and ISI Web of
Knowledge, using the grouped search terms (biomarker*
OR marker* OR metabolite* OR biokinetics OR kinetic*
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women OR patient* OR volunteer* OR participant*)
AND (trial OR experiment OR study OR intervention)
AND (urine OR plasma OR serum OR blood OR excre-
tion) AND (intake OR meal OR diet OR ingestion OR
consumption OR eating OR drink* OR administration).
For the BFI for cocoa, AND (cocoa* OR chocolate* OR
cacao* OR Theobroma) was added, and for the BFI for
liquorice, AND (liquorice OR liquorice) was added.
Three independent reviewers (CCJRM, EAA and
EMB-B) selected the papers in a process outlined in
Fig. 1. Only English papers were included, and no re-
striction was applied for the publication dates (searches
for cocoa and liquorice biomarkers were done up to
October 2016 and March 2017, respectively). Papers de-
scribing the effect on physiology, bio stability and/or
drug metabolism were excluded. Furthermore, we ex-
cluded papers that examined chocolate products without
cocoa (for example white chocolate) and liquorice prod-
ucts without liquorice root extract (for example red
liquorice). Animal studies were also excluded, since it re-
mains to be determined whether animal models are valid
models for examining the absorption, distribution, me-
tabolism and excretion of compounds in humans [24].
Initially, only titles and abstracts were screened to deter-
mine if they satisfied the selection criteria. Any disagree-
ments between the reviewers were resolved through
consultation. Next, full-text papers were retrieved forFig. 1 Flowchart selection of papers for biomarkers of chocolate and liquo
up to October 2016 and March 2017, respectivelythe selected titles. Additional papers were identified
from reference lists of the retrieved papers and from the
selected book chapters or reviews, called hand searches.
Again, three independent reviewers (CCJRM, EAA and
EMB-B) assessed the obtained papers to ensure that they
were in agreement with the inclusion criteria. A data
collection form was designed to streamline the process
of extracting relevant information from the selected
studies. This form contained the following items: dietary
factor, dose of intervention, study design, number of
subjects, analytical method, sample type, discriminating
metabolites (BFIs), notes and primary reference(s).
Specificity evaluation of the identified biomarkers
To evaluate the apparent specificity of each of the identi-
fied candidate BFI, a second search step consisting of two
parts was performed. Firstly, the compound databases
HMDB (http://www.hmdb.ca/), FooDB (http://foodb.ca/)
and Phenol-Explorer (http://phenol-explorer.eu/) were
used to screen the identified biomarkers of food intake. If
a compound was found to be present in non-cocoa- or
non-liquorice-related foods, it was removed from the se-
lection. Secondly, an additional search was performed for
the remaining selection, using combinations of the
grouped search terms (“the name and synonyms of the
compound”) AND (biomarker* OR marker* OR metabol-
ite* OR biokinetics OR biotransformation) AND (trial OR
experiment OR study OR intervention) AND (human*rice intake. Searches for 440 cocoa and liquorice biomarkers were done
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ticipant*) AND (urine OR plasma OR serum OR blood
OR excretion) AND (intake OR meal OR diet OR inges-
tion OR consumption OR eating OR drink* OR adminis-
tration) in any of the listed databases above or Google
Scholar. If the compound was found to be present in
non-cocoa- or non-liquorice-related foods in this second
search, it was removed from the selection.
Validity of the identified biomarkers
For the final selection of identified BFIs, the validity was
assessed. For this, we have used the method proposed by
Dragsted et al. [25]. An elaborate explanation on how
the validity was assessed, including the pre-defined cri-
teria; how the validity questions were constructed; and a
discussion on the strengths and weaknesses of this
method can be found in the paper of Dragsted and col-
leagues [25]. In short, the validity was assessed via an-
swering nine questions, where possible answers were Yes
(Y), No (N) or unknown/uncertain (U) where appropri-
ate. If Y was answered to a question, this would increase
the assumed validity of that specific biomarker. The
questions taken into consideration were related to
current knowledge about biological, analytical and nutri-
tional aspects of the methodology and are based on a
thorough search of previous literature. The questions
were as follows: (1) Is the marker compound plausible as
a specific BFI for the food or food group (chemical/bio-
logical plausibility)? (2) Is there a dose-response
relationship at relevant intake levels of the targeted food
(quantitative aspect)? (3) Is the single-meal time-
response relationship described adequately to make a
wise choice of sample type and time window (single-
dose kinetics)? (4) Is the biomarker kinetics for repeated
intakes of the food/food group described adequately
providing the frequency of sampling needed to assess
habitual intake (e.g. the cumulative aspects: does the
biomarker accumulate in the body over time after re-
peated intakes?)? (5) Has the marker been shown to be
robust after intake of complex meals reflecting dietary
habits of the targeted population (robustness)? (6) Has
the marker been shown to compare well with other
markers or questionnaire data for the same food/food
group (reliability)? (7) Is the marker chemically and bio-
logically stable during bio specimen collection and stor-
age, making measurements reliable and feasible? (8) Are
analytical variability (CV%), accuracy, sensitivity and
specificity known as adequate for at least one reported
analytical method? (9) Has the analysis been successfully
reproduced in another laboratory (reproducibility)? In
the end, the number of times a Y was given per bio-
marker was added, in order to get insight in the validity
of a selected biomarker. The higher this number, the
more is known about the compound, the higher itsassumed validity. This score will therefore reflect the
current level of validity of that particular compound and
pinpoints what additional research is needed to increase
the validity of that particular compound.
Results
Candidate BFIs, identification
Cocoa (products) BFIs
A total of 414 potentially relevant papers were identified
from searches in PubMed, Web of Science and Scopus.
After a first screening of the title and abstract, 55 papers
were collected as full text and assessed for further
inclusion. Then, 20 papers were excluded due to either
inappropriate study designs (e.g. animal studies), unre-
ported cocoa or chocolate intakes or unreported metab-
olites/markers. Finally, two additional papers were
identified via hand searches and added to the list, which
lead to a total inclusion of 37 papers (Fig. 1). Interven-
tion studies (n = 34) were the most frequently employed
methods to determine candidate BFIs for cocoa
(products) (Additional file 1: Table S1). In these inter-
vention studies, the participants consumed the following:
cocoa-based beverages (n = 20), chocolate (n = 8), a mix-
ture of chocolate and cocoa beverages (n = 2), cocoa-based
nut cream and/or polyphenol capsules (n = 2) and cocoa
extract as part of a ready-to-eat meal (n = 1). Of the 34
intervention studies, there were 16 acute crossover stud-
ies, 12 acute single-dose studies, 3 crossover intervention
studies (ranging from 4 to 6 weeks), 3 parallel intervention
studies (ranging from 5 days to 6 months) and 2
single-arm intervention studies (4 and 12 weeks). Only 2
observational studies [26, 27] using estimated
self-reported dietary intake data reported candidate BFIs
for cocoa and cocoa-product consumption. The most
commonly used bio samples were urine (n = 26) and
plasma (n = 18). Urine was collected mainly as 24-h urine
(n = 16), but also as spot urine (n = 7), as 8-h urine (n = 1)
and as 72-h urine (n = 2). Number of subjects ranged from
1 up to 59 in the intervention studies and up to 481 for
the cross-sectional study. Furthermore, 28 studies used a
targeted approach to determine candidate BFIs, and 10
studies used an untargeted approach, by which more com-
pounds could be identified. Among the selected papers, a
total of 164 different compounds were found as candidate
BFIs for cocoa (products) intake (Additional file 1:
Table S1). (±)-Catechin and (−)-epicatechin derivatives
were by far the group of metabolites most reported after
cocoa intake, followed by hydroxyphenylvalerolactones,
hydroxyphenylvaleric acids and methylxanthines.
Liquorice (products) BFIs
A total of 90 potentially relevant papers were identified
from searches in PubMed, Web of Science and Scopus.
After a first screening of the title and the abstract, 13
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ther inclusion. Then, 5 papers were excluded due to ei-
ther inappropriate study designs (e.g. animal studies),
unreported liquorice intakes or unreported metabolites/
markers. No additional papers were obtained via hand
searches, leading to a total inclusion of 8 papers (Fig. 1).
All the included studies were intervention studies to de-
termine candidate BFIs for liquorice (products) (Table 1).
In these intervention studies, the participants consumed
isolated compounds of liquorice (n = 4), solid liquorice
(n = 2) and liquid liquorice (n = 1) or consumed a mix-
ture of a compound or solid liquorice (n = 1). In the
eight papers, there were four acute single-dose studies,
two acute crossover studies, two parallel single-dose
studies, two parallel placebo-controlled intervention
studies (1 and 4 weeks) and one parallel intervention
study (5 days). No observational study using estimated
self-reported dietary intake data reported candidate BFI
liquorice (product) consumption nor were there any lon-
ger term studies performed, as the longest study was
4 weeks. Again, plasma and urine were the most com-
monly used bio samples, n = 7 and n = 4, respectively.
Multiple spot urine collections were used in two studies,
prolonged collection of urine (for 4 and 5 days) was used
in two other studies, and one study collected 24-h urine.
The number of subjects ranged from 1 up to 60.
Furthermore, all studies used a targeted approach to de-
termine candidate BFIs. Among the selected papers, a
total of four different compounds were found as candi-
date BFIs for liquorice (products) intake (Table 1),
namely, 18-glycyrrhetinic acid (18-GA), 18-GA
glucuronides, 3β-monoglucuronyl-18β-glycyrrhetinic acid
(3-MGA) and glabridin.
Specificity and validity of the identified BFIs
Cocoa (products) BFIs
The specificity of each of the identified candidate BFI
was evaluated via a second search step. First, the 164
candidate BFIs were screened for specificity for cocoa or
cocoa products in the compound databases HMDB,
FooDB and Phenol-Explorer. Based on the presence in
other foods, 63 markers were removed from the selec-
tion. Three turned out to have an unclear formulation
(e.g. missing information on the place of side chains)
and were therefore excluded. Based on the search results
in the compound databases, the following metabolites
were removed because of their presence in other food:
epicatechins, catechins and vanillic acid. Important to
note is that most of their biotransformation products
(e.g. glucuronides and sulfates), a total of 27 metabolites,
were not found in the compound databases. As it is
known that these biotransformation products are all re-
lated to epicatechins, catechins or vannilic acid, they
were also removed from the selection. Furthermore, 11metabolites of caffeine (theobromine, paraxanthine,
theophylline, and their biotransformation products) were
removed from the selection, since these metabolites are
produced in the gut microbiota upon intake of food
products containing caffeine, such as coffee, tea or cola
(source: HMDB), and they were therefore suspected not
to be specific BFIs for chocolate. The specificity of the
remaining 61 candidate BFIs was further examined by
performing additional searches in Scopus, ISI Web of
Science, PubMed or Google Scholar, following the syn-
tax explained in the “Materials and methods” section.
Hydroxyphenylvaleric acids and hydroxyphenylvalerolac-
tones were found to be microbial-derived metabolites
from polyphenol intake (flavan-3-ols, flavonols and flava-
nones) [28–30] and were therefore suspected not to be
specific BFIs for chocolate intake but markers for all
polyphenol-containing foods, such as almonds or tea
[28] (removal of 30 metabolites). N-Phenylpropenoyl-
L-amino acids are known to be particularly common not
only in cocoa but also in coffee and other plant-based
foods such as red clover [31, 32] and were therefore re-
moved from the selection (removal of 13 metabolites).
Furthermore, a ketone body (3-hydroxybutyrate) and
other endogenous metabolites (tyrosine sulfate,
N-methylguanine, methylglutarylcarnitine, guanidinoace-
tate) were removed from the selection [27, 33–35]. And
lastly, metabolites related to protein intake (xanthurenic
acid, indoxyl-sulfate, 4-cresol sulfate [36, 37]), vegetable
intake (phenylacetylglutamine [38, 39]), coffee intake
(furoylglycine [40]), tea intake (cyclo(Ser-Tyr), cyclo(Pro-
Pro) [41]), beer intake (cyclo(Propylalanyl), cyclo(Pro-Pro)
[42]), aspartame intake (cyclo(Aspartyl-Phenylalanyl)
[43]), nicotinic acid metabolism (hydroxynicotinic acid
[44]) and food packaging (di-iso-nonyl phthalate,
di-(2-ethylhexyl)phthalate [45, 46]) were also removed
from the selection. This meant that none of the currently
identified BFIs for cocoa (products) made the final selec-
tion, and therefore, the validity was not checked for any of
the candidate BFIs.
Liquorice (products) BFIs
The specificity of each of the identified candidate BFI for
liquorice (products) was also evaluated via a second
search step. First, the four candidate BFIs were screened
for specificity for liquorice (products) in the compound
databases HMDB, FooDB and Phenol-Explorer. The
compound 18-GA glucuronide could not be found in
any of the compound databases. However, it is known to
be the product of the hepatic metabolism of 18-GA [47],
and therefore, it was excluded from further evaluation.
The other three compounds were found in the databases
HMDB and FooDB and were linked to the presence in
herbs/spices (18-GA, glabridin) or were known as a
sweetener (3-MGA). 3-MGA is also a metabolite of GA
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Michielsen et al. Genes & Nutrition  (2018) 13:22 Page 8 of 13and is known to be excreted via urine in small quantities
and to be a possible biomarker for liquorice-induced ad-
verse effects [19, 48]. Therefore, we decided to include
3-MGA for further evaluation. In Table 1, an overview is
presented of the studies on liquorice BFIs, including de-
tails on dose used in the study, number of subjects in-
cluded, which analytical method was used to analyse the
samples, which BFIs were found and the primary refer-
ence. The specificity of all three candidate BFIs was fur-
ther examined by performing additional searches in
Scopus, ISI Web of Science, PubMed or Google Scholar,
which gave us no indication that these metabolites were
related to the intake of other food products. On the
basis thereof, and on the eight originally included pa-
pers, the validity of the three selected candidate BFIs for
liquorice (products) was evaluated (Table 2). As can be
seen in Table 2, the compound 18-GA in urine after
liquorice (product) consumption had the highest as-
sumed validity; however, uncertainty still remains about
its specificity, since liquorice root extract itself is used in
many other products, such as chewing gum, other con-
fectionary or beverages (question 1) [19, 47, 49, 50]. Kra-
henbuhl et al. [51] observed a clear dose-response
relationship for 18-GA in plasma; however, the concen-
tration GA used in this study was comparable to an in-
take of liquorice ranging from 1.7 to 5.2 kg; therefore,
no relevant intake levels of the targeted food were exam-
ined in this study. In the study of Kerstens et al. [52],
50–200 g of liquorice were consumed, showing a
dose-response relationship of 18-GA in urine (question
2). 18-GA was found to be traceable in urine after the
intake of 50 g of solid liquorice, and around 0.04% of the
total intake could be traced back after 51 h in total [52].
A peak in 18-GA concentration was measured after 6 h
in the blood after the consumption of 200 g of solidTable 2 Evaluation of the validity of the identified candidate bioma
Metabolite Bio fluid Q1 Q2 Q
Candidate liquorice biomarkers of food intake
18-glycyrrhetic acid Plasma U U Y
Serum U U Y
Blood U U Y
Urine U Y Y
3β-monoglucuronyl-18β-glycyrrhetinic acid Urine U U N
Glabridin Plasma U U U
Y yes, N no, U unknown
Q1: Is the marker compound plausible as a specific BFI for the food or food group (
Q2: Is there a dose-response relationship at relevant intake levels of the targeted fo
Q3: Is the single-meal time-response relationship described adequately to make a w
Q4: Is the biomarker kinetics for repeated intakes of the food/food group described
intake (e.g. cumulative aspects)?
Q5: Has the marker been shown to be robust after intake of complex meals reflecti
Q6: Has the marker been shown to compare well with other markers or questionna
Q7: Is the marker chemically and biologically stable during bio specimen collection
Q8: Are analytical variability (CV%), accuracy, sensitivity and specificity known as ad
Q9: Has the analysis been successfully reproduced in another laboratory (reproduciliquorice [53], or between 1.5 and 40 h in urine after the
consumption of 600 mg of the compound glycyrrhizin
(content comparable to 353 g of liquorice, Table 1) [19].
18-GA was also traceable in 24-h urine after the con-
sumption of 1500 mg of the compound GA (content
comparable to 882 g of liquorice, Table 1) [51]. In serum,
a peak was observed after 2–4 h of the consumption of
500 mg of the compound GA [54], and in plasma, the
peak time was after 3–4 h after the consumption of 21 g
of liquorice extract [55], or 500 mg and higher concen-
trations of the compound GA [51]. Best sampling time
for 3-MGA in urine was unknown, since time to max-
imum peak height ranged from 1.5 to 39.5 h. This high
interindividual variability in time to maximum peak
height was likely caused by differences in metabolism
rate and enterohepatic cycling of the compound [19]
(question 3). None of the studies examined repeated in-
takes of liquorice, or isolated compounds of liquorice
roots (question 4). In plasma, serum and urine, 18-GA
was measured after subjects continued with their habit-
ual diet during the measurements (question 5) [50–55].
Since none of the studies was an observational study, or
included questionnaire data, the answers to question 6
were “no” for all candidate BFIs. Kerstens et al. [52] did
examine whether 18-GA could be used to detect
whether two patients had consumed liquorice, even if
the patients denied having eaten liquorice-containing
products. They observed that it was indeed possible to
detect liquorice intake via measuring 18-GA in urine,
after which the patient indeed admitted to have eaten
liquorice containing products. Unfortunately, data on ac-
tual liquorice intake (via for example food frequency
questionnaires or 24-h recalls) were not recorded in this
study. Question 7 concerned the chemical and biological
stability during specimen collection and storage. In therkers of food intake for liquorice
3 Q4 Q5 Q6 Q7 Q8 Q9 Sum References
U Y N U Y N 3 [50, 51, 55]
U Y N U Y N 3 [54]
U N N U Y N 2 [53]
U Y N U Y N 4 [51–53]
U Y N U Y N 2 [19]
U N N U N N 0 [56]
chemical/biological plausibility)?
od (quantitative aspect)?
ise choice of sample type and time window (single-dose kinetics)?
adequately providing the frequency of sampling needed to assess habitual
ng dietary habits of the targeted population (robustness)?
ire data for the same food/food group (reliability)?
and storage, making measurements reliable and feasible?
equate for at least one reported analytical method?
bility)?
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ples were stored at 4 °C [19, 54] or − 20 °C [52, 53], and
blood, plasma and serum samples were stored at − 20 °C
[50–53, 55] before continuing with the analyses. In some
cases, no information was available about the storage
temperature of the samples [56], and for all eight stud-
ies, it was unclear how long the samples had been
stored. Analytical variability for measuring 18-GA in
plasma was 3% [51]; in urine, CV% was between 6 and
9.3% [51, 53]; in serum, there was a 2.1% within assay
variability and 8.5% between assay variability [54]; and in
blood, CV% was between 4.6 and 6.3% [53]. For 3-MGA,
the repeatability of the measurements within and be-
tween days was tested, with peak height 4.88 and 7.21
RSD%, respectively, and peak area 2.61 and 6.21 RSD%,
respectively [19]. In the papers of Raggi et al. [55], Aoki
et al. [56] and Ploeger et al. [50], no details about analyt-
ical variability were presented (question 8). Lastly, none
of the analyses described in the eight selected papers
were reproduced by another laboratory. The analyses
used were either described in the paper for the first time
[19, 50, 52, 53, 55] or had previously been performed at
their own lab [51, 54, 56] (question 9).
Discussion
The present systematic review examined the current sta-
tus of candidate BFIs for the consumption of cocoa
(products) and liquorice. In total, 37 relevant papers
were included for cocoa (products) [26, 27, 32–34, 44,
57–87], and 8 relevant papers were included for
liquorice (products) [19, 50–56]. For cocoa (products),
164 different compounds were identified as candidate
BFIs in the 37 obtained papers. After evaluating the spe-
cificity of these compounds, none of these candidate
BFIs turned out to be specific for cocoa (products).
Therefore, the validity of these compounds was not fur-
ther examined. For liquorice (products), 4 different com-
pounds were identified as candidate BFIs in the 8
obtained papers. After evaluating the specificity and the
validity of these 4 compounds, 18-GA in urine was
found to have the highest assumed validity.
Regarding the 164 cocoa (products) BFIs
(Additional file 1: Table S1), none of the identified
compounds was specific. Our results indicated that most
of the identified BFIs for cocoa (products) were also
found or are expected to be found after the consumption
of foods such as tea, coffee or red wine. This is due to
similarities in the composition of these foods, such as a
high polyphenol content or the presence of caffeine
compounds [88–91]. Only a few randomised trials (both
short and long term) have compared the metabolite pro-
file after consumption of cocoa (products) with other
products showing a similar metabolite profile, such as
the metabolite profiles observed after tea [63, 71] orcoffee [63]. Up till now, no metabolites were obtained
that could discriminate between these food products.
However, only a small amount of metabolites was mea-
sured in these studies via targeted approaches. With
untargeted approaches, a higher number of compounds
can be measured in bio fluids and therefore might eluci-
date compounds that are specific and valid BFIs for
cocoa (products). Before any conclusion can be drawn
about the specificity of the identified BFIS for cocoa
(products), more randomized intervention studies com-
paring food products with a similar metabolite excretion
pattern, using untargeted approaches, are needed. Fur-
thermore, it remains to be explored whether the
dose-response relationship is equal after consuming for
example same amounts of tea and a cocoa drink [63].
Another important point to consider is that the way of
processing of the cocoa beans, the cocoa variety and the
origin of the cocoa bean can affect the final concentra-
tion of compounds in the cocoa product [92]. In
addition, cocoa beans are subject to seasonal variation,
again affecting concentrations of several compounds in
the beans [93, 94]. In this review, we focused on single
BFIs for cocoa intake, which turned out to be nonspe-
cific. A combination of several biomarkers, a so-called
biomarker profile or panel of biomarkers might however
increase the specificity for cocoa intake. Garcia-Aloy and
colleagues [95] have examined this possibility in an
untargeted study and found a combined model for cocoa
consumption that included 7-methylxanthine and dihy-
droxyphenylvalerolactone glucuronide. This combined
model was a better discriminant for cocoa consumption
compared to all individual metabolites. It is essential to
explore whether this combination of compounds will
also discriminate cocoa (products) intake from tea intake
or coffee intake.
The four identified liquorice BFIs (Table 1), 18-GA,
18-GA glucuronides, 3-MGA and glabridin, were only
described in relation to liquorice intake or liquorice root
extracts. However, liquorice root extracts are known to
be used in a variety of products, such as different sweets,
chewing gums, chewing tobacco and tea, or even in
(alcoholic) drinks and medicinal products, often as a
sweetening or flavouring agent [19, 47, 49, 50]. It will
therefore be necessary to examine the relative content
and contribution of liquorice extract in these products
and in the habitual consumed diets overall. An import-
ant point to consider is that the content of liquorice root
extracts may vary from product to product, depending
on the characteristics the producer desires for that prod-
uct, which causes variation in the final concentrations of
liquorice root extracts in these products. For example, in
the solid liquorice that was consumed in the included
studies, the GL content varied from 0.05 up to 0.23%.
18-GA in urine was the most promising and most
Michielsen et al. Genes & Nutrition  (2018) 13:22 Page 10 of 13studied candidate BFI out of the three candidates for
liquorice (products). To increase its validity, studies on
repeated intake, habitual food consumption, dietary pat-
terns, stability during storage and reproducibility of the
methods between labs are still needed. Important to note
is that in all studies examining liquorice biomarkers,
subjects consumed 68 g of liquorice or more (when
standardized to the average glycyrrhizin content in
liquorice confectionary of 0.17% [96], this is equivalent
to an intake of GL of 116 mg), while the European Sci-
entific Committee on Food advises that ingestion of
liquorice should not exceed 58 g per day (equivalent to
an intake of 100 mg GL per day) [96]. Therefore, it is
crucial to investigate whether 18-GA is still a reliable
biomarker when measured after the intake of a low dose
of liquorice, or after repeated intake of low doses of
liquorice. This is especially important since some studies
were unable to measure 18-GA in urine, because the
amount was below the detection limit at lower concen-
trations of intake [51, 54]. Clearly lacking in the litera-
ture for all candidate BFIs for liquorice were long-term
intervention studies, dietary pattern studies and observa-
tional studies. Currently, the longest study had a dur-
ation of 4 weeks. However, this study was done using
liquorice flavonoid oil in which glycyrrhizin was almost
removed from the product (< 0.005%) [56]. Conse-
quently, this study did not give us information about the
consumption of solid liquorice or other products using
liquorice root extracts, which have a higher glycyrrhizin
content. The lack of observational and dietary pattern
studies makes it impossible to properly validate any of
the three found candidate BFIs; therefore, these studies
are urgently needed. Moreover, we only found the poly-
phenol glabridin as candidate BFI for liquorice intake;
however, there are more polyphenols known to be
present in liquorice roots. For example, Vaya et al. [97]
have isolated hispaglabridin A, hispaglabridin B,
4′-O-methylglabridin, formononetin and glabridin itself
from liquorice roots. It should be further examined what
the exact contribution of these polyphenols is in
liquorice (products) and whether these compounds
could be possible BFIs for liquorice (products). For
18-GA and glabridin, commercial standards are available;
for 18-GA also, a non-commercial standard is available
through FoodComEx (Food Compound Exchange, food-
comex.org), an online catalogue of pure compounds made
available by academic laboratories [98].
Conclusions
In this paper, we have identified potential BFIs for cocoa
(products) and liquorice (products). For cocoa
(products), none of the individual BFIs were found to be
specific. However, a combination of individual BFIs
might lead to discriminating profiles between cocoa(products) and foods with a similar composition. This
needs to be further explored. We did identify 18-GA as
a promising candidate BFI for liquorice; however, im-
portant information on its validity is still missing, and
therefore, more research is needed. This systematic re-
view shows that there is still an urgent need for research
to identify specific and valid biomarkers of the con-
sumption of cocoa (products) and liquorice (products).
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